Your session is about to expire
← Back to Search
Physostigmine for Smoking (nic_physo Trial)
N/A
Waitlist Available
Led By Kelly Cosgrove, PhD
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
have no history of a neurological or psychiatric disorder (DSMIV Axis 1 and 2) other than schizophrenia in schizophrenia subgroup
who are able to read and write
Timeline
Screening 3 weeks
Treatment Varies
Follow Up first 150 minute scan at baseline, second 150 minute scan start 10 minutes post physostigmine administration
Awards & highlights
nic_physo Trial Summary
This trial will measure the effects of smoking and schizophrenia on the availability of nicotinic receptors and dopamine levels.
Eligible Conditions
- Smoking
- Schizophrenia
nic_physo Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belownic_physo Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ first 150 minute scan at baseline, second 150 minute scan start 10 minutes post physostigmine administration
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~first 150 minute scan at baseline, second 150 minute scan start 10 minutes post physostigmine administration
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in Acetylcholine (ACh) Levels After Physostigmine Administration as Confirmed by PET Images.
Change in Dopamine (DA) Levels After Amphetamine Administration as Confirmed by PET Images.
Side effects data
From 2020 Phase 4 trial • 19 Patients • NCT0309062011%
Vomitnig
11%
Oversedation
100%
80%
60%
40%
20%
0%
Study treatment Arm
Physostigmine
Lorazepam
nic_physo Trial Design
1Treatment groups
Experimental Treatment
Group I: physostigmine and amphetamineExperimental Treatment1 Intervention
There is only one arm to the study. All subjects will receive physostigmine and amphetamine.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Physostigmine
2009
Completed Phase 4
~150
Find a Location
Who is running the clinical trial?
National Institute on Drug Abuse (NIDA)NIH
2,453 Previous Clinical Trials
2,596,726 Total Patients Enrolled
66 Trials studying Smoking
22,540 Patients Enrolled for Smoking
Yale UniversityLead Sponsor
1,839 Previous Clinical Trials
2,728,963 Total Patients Enrolled
32 Trials studying Smoking
9,590 Patients Enrolled for Smoking
National Institutes of Health (NIH)NIH
2,682 Previous Clinical Trials
6,930,718 Total Patients Enrolled
35 Trials studying Smoking
14,135 Patients Enrolled for Smoking
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger